Segal Trials is honored to have contributed significantly to the FDA approval of COBENFYtm (xanomeline and trospium chloride), a groundbreaking first-in-class muscarinic agonist developed by Bristol ...
Segal Trials contributed to the FDA approval of COBENFY™, a new schizophrenia treatment, highlighting their role in advancing ...
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
In the U.S., prescription drug spending rose 8.4% in 2022 to $405 billion ... One of the drugs Royalty Pharma owns a stake in ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback